Real-World Clinical Studies in Acute Leukemia
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 25
Special Issue Editor
Interests: acute myeloid leukemia (AML); acute lymphoid leukemia (ALL); target therapy in onco-hematology; stem cell transplantation (SCT)
Special Issue Information
Dear Colleagues,
Real-world clinical studies on acute leukemias are important because they provide valuable insights into treatment options and disease outcomes. These studies also allow us to evaluate the tolerability and efficacy of new and rapidly approved drugs in a real-life context among unselected patient populations, unlike those included in phase III clinical trials with selective criteria. This Special Issue, titled "Real-World Clinical Studies in Acute Leukemia", aims to collect multicentric, real-life experiences with new and emerging treatment options, such as hypomethylating agent combinations, venetoclax combinations, other targeted therapies, minimal residual disease (MRD)-driven treatments, post-stem cell transplant (SCT) maintenance or salvage therapy, in acute myeloid or lymphoid leukemia in both first-line and relapsed/refractory settings.
Prof. Dr. Anna Candoni
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia (AML)
- acute lymphoid leukemia (ALL)
- refractory/relapsed leukemia
- target therapy
- FLT3 inhibitors
- IDH (1-2) inhibitors
- venetoclax
- hypomethylating agents
- stem cell transplantation (SCT)
- minimal residual disease (MRD)
- MRD-driven therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
